Our laboratory is currently testing the ability of PLG nanoparticles encapsulating either the immunodominant AQP4 T cell peptide epitope or full-length recombinant AQP4 to both prevent and treat ongoing clinical disease in experimental animal models of NMO (89, 90). Here, AQP4 is linked to neuromyelitis optica.